BioCentury
ARTICLE | Politics & Policy

ICER panel votes against elagolix for endometriosis

July 12, 2018 10:53 PM UTC

An ICER panel showed little confidence in the clinical effectiveness of elagolix (ABT-620) from AbbVie Inc. (NYSE:ABBV) to treat endometriosis, voting Thursday that evidence is not adequate to support a net health benefit over other treatments or no treatment.

ICER's New England Comparative Effectiveness Public Advisory Council (CEPAC) voted 1-11 that elagolix's net health benefit was superior to no treatment, and 0-12 that elagolix's net health benefit was superior to leuprorelin acetate or the hormonal contraceptive medroxyprogesterone. As the current evidence did not support elagolix's clinical superiority, the panel did not vote on the therapy's long-term value...

BCIQ Company Profiles

AbbVie Inc.